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In 2006, a clinical trial with the CD28 superagonistic antibody TGN1412 in London turned into a catastrophe.
Studies are beginning to unravel the difference between the human and preclinical animal response to the
antibody.Soon after the discovery of CD28 ‘‘super-
agonists’’ (CD28SAs), it was recognized
that these antibodies can induce a prefer-
ential activation and expansion of immu-
nosuppressive regulatory T cells in rat
and mice (Lin and Hu¨nig, 2003; Hu¨nig,
2007) and that these particular properties
can be used to ameliorate the onset, the
progression, and the clinical course of
experimental autoimmune diseases (for
a review, see Hu¨nig [2007]).
On the basis of these promising
findings, it seemed possible to deploy
CD28SAs for in vivo modulation of human
autoimmune diseases. Consequently, af-
ter an enormous amount of preclinical
data had been collected (including exper-
iments involving cynomolgus and rhesus
monkeys), a phase I clinical trial was con-
ducted on March 13, 2006 at the North-
wick Hospital in London, UK. During that
trial, the humanized CD28 superagonist
TGN1412 was administered to six healthy
volunteers. Unfortunately, the trial turned
into a catastrophe because TGN1412, un-
expectedly, induced a rapid and massive
cytokine storm that caused severe and
life-threatening adverse effects in all six
volunteers (Suntharalingam et al., 2006).
A tremendous amount of effort has
been invested in understanding what
went wrong at the trial, so what more
do we know two years after the London
incident that we didn’t appreciate before?
Regulatory Measures Taken in the
Aftermath of the TGN1412 Incident
Immediately after the TGN1412 incident, an
investigation was initiated by the UK Medi-
cines and Healthcare products Regulatory
Agency (MHRA) that had approved the
TGN1412 trial. This investigation came tothe conclusion that the adverse incidents
did not involve errors in the manufacture of
TGN1412 or in its formulation, dilution, or
administration to trial participants and that
therefore unpredicted biological action of
the drug in humans accounted for the dev-
astating effects in the trial participants
(http://www.mhra.gov.uk/home/idcplg?Idc
Service=GET_FILE&dDocName=CON202
3821&RevisionSelectionMethod=Latest
Released). This notion raised concerns re-
garding whether currently available knowl-
edge is sufficient to tame superantibody
drugs.
A number of European agencies, in-
cluding the French, British, and German,
formulated recommendations to improve
safety of first-in-human clinical trials
(for review, see Schneider and Kalinke
[2007]). The Expert Scientific Group con-
vened in the UK to further investigate the
TGN1412 incident and to develop recom-
mendations to minimize risks associated
with phase I clinical trials of innovative
medicinal products. Repetitions of pre-
clinical experiments, including nonhuman
primate studies, commissioned by the Ex-
pert Scientific Group recapitulated the
findings as summarized in the original in-
vestigator’s brochure of TeGenero (the
company that developed TGN1412).
These results and a total of 22 recommen-
dations addressing the transition from
preclinical to clinical development, the
clinical development, regulatory aspects,
and future perspectives were published
at the end of 2006 in a comprehensive fi-
nal report (Duff, 2006). On the basis of
the above considerations, the Committee
for Medicinal Products for Human Use
(CHMP) at the European Medicines
Agency (EMEA) developed a guidelineImmon strategies to identify and mitigate risks
for first-in-human clinical trials that is in ef-
fect since September 2007 and that is not
only applicable to mAbs and other biolog-
icals but also to conventional medicinal
products (EMEA, 2007).
Nevertheless, although effective regu-
latory measures were undertaken in a
timely manner that definitely further
improve overall safety of phase I clinical
trials, the most critical scientific question
that was put forward in one of the first
reports after the TGN1412 incident, the in-
vestigation report by MHCR, is still only
insufficiently solved, i.e., why the resulting
TGN1412 activity seen in humans was not
predicted from apparently adequate pre-
clinical testing.
In order to solve this puzzle, it will be
mandatory to carefully (re)assess func-
tional responses of CD28SA-stimul-
ated human, rat, and monkey T cells by
biochemical, cell-biology, and molecu-
lar-biology means. Indeed, if the spe-
cies-specific differences are understood
on the molecular level, it might be possi-
ble to avoid incidents such as the one in
London in the future and to predict poten-
tial adverse effects already in the preclin-
ical phase of drug development.
Recent studies have now begun to
shed some light into the question of why
rodent and monkey T cells behave diff-
erently when compared to human T
lymphocytes upon CD28SA stimulation.
T Cell Activation by CD28
Superagonists
One paradigm of T cell activation is the re-
quirement of two simultaneously applied
signals (Schwartz, 1992): The first signal
is antigen dependent and is mediatedunity 28, May 2008 ª2008 Elsevier Inc. 591
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Commentaryvia the T cell receptor (TCR), whereas the
second signal is antigen independent and
is provided by costimulatory receptors,
such as CD28. In vivo, the first signal is
mediated by peptide-MHC complexes
that bind to the TCR, whereas the second
signal is initiated after CD28 has been en-
gaged by its natural ligands, CD80 and
CD86, both of which are expressed on
mature dendritic cells.
Under in vitro conditions, the second
signal can be mimicked by so-called con-
ventional CD28 antibodies (Acuto and
Michel, 2003). According to the above
paradigm, these reagents support T cell
activation only in combination with a pri-
mary, TCR-mediated, stimulus (e.g., pro-
vided by TCR antibodies). Approximately
ten years ago, a new group of CD28 anti-
bodies, now called CD28 superagonists
(CD28SA) or mitogenic CD28 mAbs, has
been described (Bischof et al., 2000;
Dennehy et al., 2007; Dennehy et al.,
2003; Tacke et al., 1997). In contrast to
conventional CD28 antibodies, CD28
superagonists are capable of triggering
the activation of rat, mouse, and human
T lymphocytes upon binding to CD28
alone. How CD28SAs induce polyclonal
T cell activation (and thus provide signal
one and two simultaneously) is still not
completely understood.
Signaling Properties of CD28SAs
Before the London trial, the signaling prop-
erties of superagonistic CD28 mAbs had
been most extensively studied in rat and
mouse T cells (Dennehy et al., 2003;
Lu¨hder et al., 2003). Only recently, sig-
naling signatures of anti-human CD28
superagonists have also been assessed
(Dennehy et al., 2007; Sester et al., 2007;
Stebbingset al., 2007; Waibler etal., 2008).
Overall, it appears as if the signaling
events generated by anti-rat and anti-
mouse versus anti-human CD28SAs are
rather similar. For instance, signaling via
both anti-rat and anti-human CD28SAs
depends on Src-family protein tyrosine
kinases and activation of the SLP76 sig-
nalosome (which is required for inducing
transmembranous calcium flux and con-
sists of the adaptor protein SLP76, the
nucleotide exchange factor Vav, the Tec-
kinase Itk, and phospholipase Cg). Fur-
ther, anti-rat and anti-human CD28SAs
activate protein kinase Cq and ras and
Erk kinases, as well as the transcription
factors NF-ATc1 and NF-kB (Bischof592 Immunity 28, May 2008 ª2008 ElsevierTable 1. Potential Species-Specific Differences in CD28SA-Mediated Signaling
Species
Dependency on
TCR Expression
Calcium
Flux >2 hr
PI3K
Requirement
Expression
of Siglecs
Rat yes not assessed unclear not systematically
assessed
Cynomolgus not yet
assessed
yes, but very
weak
not assessed not systematically
assessed
Human yes yes, >6 hr yes lost during evolutionet al., 2000; Dennehy et al., 2003; Sester
et al., 2007; Waibler et al., 2008). How all
these signals are initiated at the plasma
membrane is still not completely under-
stood. One hypothesis is that CD28SAs
might induce massive clustering of CD28,
thereby generating signaling patches
within the membrane. However, at least
by conventional confocal microscopy, the
clusters that are produced by CD28SAs
cannot be distinguished from those gen-
erated by conventional CD28 antibodies
(Sester et al., 2007 and our own unpub-
lished data). Hence, more sophisticated
microscopic and/or biochemical studies
are required to assess this question.
Recently, it was shown that in humans
and rats, the signaling capacity of
CD28SAs depends on the expression of
a functional TCR (Dennehy et al., 2007;
Waibler et al., 2008). On the basis of these
rather surprising findings, it was hypothe-
sized that CD28 superagonists induce T
cell activation by amplifying tonic signals
that emanate from the unligated TCR and,
further, that this amplification occurs at
the level of the SLP76 signalosome (Den-
nehy et al., 2007). However, CD28SA-me-
diated signaling could also feed into the
TCR pathway upstream of this complex,
e.g., at the level of the transmembrane
adaptor molecule LAT or the protein tyro-
sine kinase ZAP70 (Waibler et al., 2008).
In rats, a particular binding site for the
adaptor protein Grb2 in the cytoplasmic
domain of CD28 appears mandatory for
CD28SA signaling because mutation of
this site impairs calcium flux and interleu-
kin-2 secretion in response to CD28SAs
(Dennehy et al., 2007). Biochemical ex-
periments further suggested that these
defects result from an insufficient activa-
tion of Itk and Vav within the SLP76 sig-
nalosome. How CD28 couples to Itk and
Vav and whether anti-human CD28SAs
employ a similar mechanism to activate
T cells is as yet unclear.
One important point that needs clarifi-
cation relates to the role of PI3 kinaseInc.(PI3K) in anti-human versus anti-rat
CD28SA-induced cytokine production. In
rat T cells, mutation of the PI3K-binding
site in the cytoplasmic domain of CD28
does not affect CD28SA-mediated induc-
tion of calcium flux and IL-2 synthesis
(Dennehy et al., 2007). In contrast, phar-
macologic inhibition of PI3K completely
abrogates CD28SA-mediated interferon-
g (IFN-g) and IL-2 production of human
T cells in vitro (Waibler et al., 2008). Col-
lectively, these data might suggest a
different requirement for PI3K in
CD28SA-mediated cytokine production
and proliferation in human versus rat T
cells. It will be of great importance to elu-
cidate this question because, if the differ-
ences between the human and rodent
system could be confirmed, this might
explain some of the particular functional
effects of anti-human CD28SAs.
We recently showed that both
TGN1412 as well as a commercially
available CD28SA, ANC28.1, induce an
extremely sustained transmembranous
calcium flux in human T cells (Waibler
et al., 2008). Moreover, the amounts of
IFN-g and IL-2 that are secreted by
ANC28.1-stimulated human T cells in vitro
strictly correlate with the duration of
calcium flux. Hence, it seems as if the
cytokine storm that was generated by
TGN1412 is strongly associated with an
extremely sustained transmembranous
calcium flux. How this flux is generated
by TGN1412 and ANC28.1 is currently
unclear. Unfortunately, it is also unknown
whether anti-rat and anti-mouse
CD28SAs induce a similarly shaped cal-
cium response as anti-human CD28SAs
(Table 1). Indeed, so far only short-term
kinetics had been performed in all experi-
ments dealing with CD28SA-mediated
calcium flux in rat and mouse T cells
(see e.g., Dennehy et al., 2003).
Human versus Monkey T Cells
A major question regarding the London
trial is why two nonhuman primate
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monkeys, did not show obvious adverse
effects upon TGN1412 treatment. This is
particularly surprising in light of the fact
that the extracellular domains of cynomol-
gus and rhesus monkey and human CD28
are completely conserved (Hanke, 2006;
Waibler et al., 2008). Further, the overall
numbers of CD28 molecules that are
expressed by cynomolgus and rhesus
monkey T cells appear to be similar, if
not identical, to human T cells. In addition,
the affinity of TGN1412 toward human
and monkey CD28 appears to be compa-
rable (Hanke, 2006; Waibler et al., 2008).
Principally two possibilities could be
envisaged (which are not mutually
exclusive) to explain differential in vivo
responses in humans and nonhuman pri-
mates. The first would be that the magni-
tude of the TGN1412 response elicited
in monkey T cells is much lower than
that in human T cells (quantitative model).
Alternatively (or additionally), TGN1412
stimulation of monkey T cells might not
activate the same intracellular signaling
pathways as it does in human cells (qual-
itative model) and, consequently, might
not induce cytokine synthesis.
Unfortunately the ‘‘qualitative model’’ is
somewhat difficult to prove because the
numbers of T cells that can be isolated
from rhesus and cynomolgus monkeys
are too low to perform well-conducted
biochemical studies. So that this problem
is avoided, it would be necessary to es-
tablish new methods such as flow-cytom-
etry assays that allow detection of phos-
phorylation events and the correlation
with the activation of various intracellular
signaling pathways in monkey T cells.
With regard to the ‘‘quantitative model,’’
we showed that the TGN1412-mediated
calcium response of monkey T cells, albeit
being also sustained, is much lower com-
pared to human T lymphocytes (Waibler
et al., 2008). Moreover, an independently
performed study came to the conclusion
that monkey peripheral blood mononu-
clear cells (PBMCs), unlike human cells,
do not produce detectable amounts of
cytokines in vitro when activated by
CD28SAs (Stebbings et al., 2007). Hence,
it appears as if monkey T cells are less
responsive toward CD28SA stimulation
than human T cells.
In this context, it was discussed whether
the TGN1412-mediated response in mon-
keys might be lower because the animalsare kept under more ‘‘sterile’’ conditions
compared to humans and that therefore
the monkey T cell population might be
more ‘‘naive.’’ However, there is currently
no convincing evidence supporting this
notion. Indeed, monkeys are not kept un-
der specified pathogen-free (SPF) condi-
tions and they also receive ‘‘normal’’
food. Moreover, the CD28SA-mediated
calciumflux and the invitro-inducible cyto-
kine production do not appear to differ
dramatically between naive and memory
human T cells (Sester et al., 2007; Waibler
et al., 2008). In summary, particular hous-
ing conditions or subtle difference in the
composition of T cell subsets are unlikely
to explain the reduced responsiveness of
monkey T cells toward TGN1412.
What else could explain the quantita-
tively different CD28SA-response of hu-
man versus monkey T cells? As reported
above, the extracellular domains of mon-
key and human CD28 are identical on
the amino acid level, and also the
TGN1412 binding of CD28 expressed by
human and nonhuman primate T cells is
comparable. However, sequence com-
parison revealed three amino acid ex-
changes in the corresponding transmem-
brane domains between humans and
nonhuman primates (Waibler et al.,
2008). These might influence the lateral in-
teractions of CD28 with other signal-
transducing molecules within the cell
membrane and thus alter the outcome of
CD28SA stimulation. For assessing this
point, it will be necessary to reconstitute
CD28-deficient T cells with CD28-swap-
ping mutants carrying the human or mon-
key transmembrane domains to subse-
quently compare CD28SA-mediated
responses in the two types of cells.
An alternate, yet attractive, hypothesis
that could explain the quantitatively differ-
ent reactivity of monkey versus human
T cells toward TGN1412 stimulation re-
lates to the differential expression of a
family of molecules called Siglecs (Table
1). Siglecs are integral membrane recep-
tors belonging to the immunoglobulin
superfamily. Within the cytoplasmic tails,
some Siglecs carry ITIMs (immunorecep-
tor-tyrosine-based inhibition motif). Upon
tyrosine phosphorylation (which occurs
by protein tyrosine kinases of the Src-
family), the ITIMs recruit tyrosine
phosphatases such as SHP1 or SHP2 to
the plasma membrane, which in turn de-
phosphorylate key tyrosine residues inImmother signaling proteins (Crocker et al.,
2007).
Strikingly, Siglecs are barely detectable
on human T cells, whereas T cells from
chimpanzees express various members
of these receptors (Nguyen et al., 2006).
Moreover, ectopic expression of Siglec-
5 (the major Siglec expressed by chim-
panzee T cells) on human T cells impairs
CD3-mediated responses, whereas the
opposite is true if Siglec-5 is cleared
from the surface of chimpanzee T cells
(Nguyen et al., 2006). These data would
support the idea that an evolutionary
loss of Siglec expression on human T cells
lowers the signaling thresholds that are
required to activate the intracellular sig-
naling machinery. However, it remains to
be determined whether rhesus and/or
cynomolgus monkey T cells express
Siglecs and whether alterations in Siglec
expression not only affect TCR-mediated
T cell responses in chimpanzees and
other monkeys but also those induced
by CD28 superagonists.
The Fc-Receptor Issue
Many antibody functions are mediated
via Fc-receptor binding. In the case
of TGN1412, the constant part was
expressed as an IgG4. The observation
that calcium flux and cytokine secretion
require crosslinking of the TGN1412 (Wai-
bler et al., 2008) raises the question of
which Fcg receptor expressing cell types
could have provided TGN1412 crosslink-
ing in vivo and whether such crosslinking
is similarly observed in nonhuman pri-
mates. In this regard, it was recently dem-
onstrated that in vitro cytokine production
of PBMC can be induced by TGN1412 in
the presence of human endothelial cells
(Stebbings et al., 2007). However, se-
quence analysis suggests that human
and nonhuman primate Fcg receptors
share a high degree of similarity (Presta
and Namenuk, 2005). Hence, it is unclear
whether endothelial cells of human and
nonhuman primate origin can similarly
crosslink CD28SA and, if so, whether
such crosslinking plays a critical role for
cytokine production in vivo and, further,
which Fc-receptor is involved.
CD28SA and Regulatory T Cells
During the preclinical phase CD28SAs
had been extensively tested in rodents
(for a review, see Hu¨nig [2007]) in which
administration of CD28SAs inducedunity 28, May 2008 ª2008 Elsevier Inc. 593
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a preferential expansion of natural regu-
latory T (Treg) cells. Proinflammatory
cytokines such as IFN-g and IL-2 were
not detected in the animals. Rather, a pro-
duction of the anti-inflammatory cyto-
kines IL-10 and IL-4 was found (Hu¨nig,
2007). The lack of production of proin-
flammatory cytokines was believed to be
due to the fact that in rodents, the expan-
sion and activation of Treg cells occur so
quickly that they suppress cytokine pro-
duction by conventional CD4+ T cells
(which clearly also become activated by
CD28SAs) before it reaches amounts
that could cause physiological changes.
A recent report extended this hypothesis
by showing that in rats, the CD28 supera-
gonist JJ316 induces two waves of T cell
activation in vivo: A fast and transient
wave (<48 hr) that affects both conven-
tional and Treg cells and a second,
delayed wave (>48 hr) that exclusively
results in the activation of Treg cells
(Mu¨ller et al., 2008). Surprisingly, although
during the first phase conventional T cells
strongly upregulate mRNA for proinflam-
matory cytokines, serum levels remain
low (Mu¨ller et al., 2008).
As we have learnt from the London trial,
this mode of CD28SA stimulation does
not hold true for the in vivo situation in hu-
mans. Moreover, despite differences in
the experimental design, three recent
studies showed production of substantial
amounts of proinflammatory cytokines af-
ter in vitro CD28SA stimulation of human T
cells or PBMCs (Sester et al., 2007; Steb-
bings et al., 2007; Waibler et al., 2008).
Although the experimental settings in
two of these studies (Sester et al., 2007;
Waibler et al., 2008) might not appropri-
ately reflect the situation in vivo (because
cytokine responses were only assessed
after crosslinking of the CD28SAs by
means of secondary antibodies), it is likely
that even if anti-human CD28SAs induce
the activation or expansion of natural hu-
man Treg cells (which still has to be dem-
onstrated), this appears to occur either
with a much slower kinetics or with much
lower efficiency compared to rodents. In
both cases, the result is the same, namely
a predominant production of proinflam-
matory cytokines by CD28SA-stimulated
human CD4+ T cells.
The implication from these in vivo and in
vitro data goes far beyond CD28SA sig-
naling. Indeed, the London incident pro-594 Immunity 28, May 2008 ª2008 Elsevier Ivided additional evidence that signals
leading to activation and/or expansion of
Treg cells presumably show subtle
differences that eventually may result in
dramatically different outcomes in the ro-
dent and human system. Hence, data that
were obtained in the mouse system can-
not be transferred to the human system
without rigorous experimental verifica-
tion. One exciting approach to address
this problem might be new developments
in the field of humanized mice. Interest-
ingly, experiments in that direction had
also been performed with a mouse anti-
human CD28 superagonistic antibody
(Legrand et al., 2006). However, from to-
day’s perspective, the relevant questions
had not been addressed in that study,
i.e., cytokine responses were not ana-
lyzed in the anti-CD28SA-treated human-
ized mice.
Conclusions
The currently available experimental data
suggest that only minor differences in
the organization and regulation of T cell
responses account for dramatic species-
specific differences that are observed
after CD28 superagonistic T cell activa-
tion and that only in-depth experimental
analysis might allow solving this puzzle.
Besides providing insights into the spe-
cies-specific organization of central
signaling pathways, such experiments
could also help to better validate con-
cepts and working models during the
preclinical phase of drug development.
In addition, to make drug development
safer, interdisciplinary activities need to
be strengthened in the future. For exam-
ple, systems-biology approaches might
help to predict potential adverse effects
of novel drugs in silico which then could
be screened for by designing appropriate
experiments. Moreover, valuable informa-
tion about novel drugs is usually depos-
ited in data collections of single pharma-
ceutical companies, but in general this
information is not easily accessible in
public domains.
Nevertheless, it should be kept in mind
that even the most sophisticated and
extensive in vitro, in vivo, and in silico
analyses may again fail to predict reactiv-
ity of agonistic biologicals in humans.
Thus, the most important safety measure
learned from the TGN1412 trial appears
to be the application of the minimal antic-
ipated biological effect level (MABEL)nc.instead of the nonobserved adverse ef-
fect level (NOAEL) for first-in-human
dose calculations. The advantage of the
MABEL approach is that it is based on
straightforward parameters such as re-
ceptor occupancy and leads to a much
lower entry dose compared to the NOAEL
calculation. Especially in the case of re-
agents with agonistic properties, this
might substantially increase the safety of
first-in-human studies.
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